KM Research Hub
← 返回论文库
待处理 入排:待复核 图源:待检查 入排置信度 0.00

A Bayesian reanalysis of the THOR trial cohort 1 using reconstructed individual patient data: interval-specific effects and clinically interpretable estimands under non-proportional hazards.

Gaku Okumura, Soichiro Yoshida, Kohei Hirose, Shugo Yajima, Wei Chen, Hiroyuki Sato, Akihiro Hirakawa, Motohiro Fujiwara, Yuki Arita, Hiroshi Fukushima, Yosuke Yasuda, Hajime Tanaka, Hitoshi Masuda, Yasuhisa Fujii

Jpn J Clin Oncol 56(11) 1437-1442

PMID42632050
PMCID-
DOI10.1093/jjco/hyag133
发表日期2026-08-22
入排依据:已见 Phase III 和 time-to-event 信号,但随机分配证据不足,需复核。
摘要

摘要

BACKGROUND: The phase 3 THOR trial (cohort 1) showed improved overall survival (OS) and progression-free survival (PFS) with erdafitinib versus chemotherapy in FGFR2/3-altered advanced urothelial carcinoma after prior programmed cell death protein 1 (PD-1) / programmed death-ligand 1 (PD-L1) inhibitor therapy. When the assumption of proportional hazards (PH) is violated, a single hazard ratio (HR) may be difficult to interpret. METHODS: We derived reconstructed individual patient data (rIPD) for OS and PFS from published Kaplan-Meier curves. PH was assessed using scaled Schoenfeld residuals and log-log plots. We fit Bayesian piecewise-exponential models with administrative censoring at τ = 24 months (OS; cut-point 12 months) and τ = 12 months (PFS; cut-point 6 months). We reported interval-specific HRs, landmark survival differences (ΔOS, ΔPFS), number needed to treat (NNT), restricted-mean survival time (RMST), and posterior probabilities for clinically meaningful thresholds. RESULTS: Statistical diagnostics indicated that the PH assumption was violated for both OS and PFS. For OS, HR was 0.59 (95% credible interval 0.41-0.84) in months 0-12 and 1.06 (0.48-2.48) in months 12-24. At 12 months, ΔOS(12) = 0.18 (0.06-0.30); conditional median NNT was 5.45. ΔRMST (0-24) = 3.02 months (0.74-5.23), with P(ΔRMST >0) = 99.5%. For PFS, the HR was 0.64 (0.45-0.89) in months 0-6 and 0.49 (0.25-1.00) in months 6-12; ΔPFS (6) = 0.16 (0.04-0.28) and ΔRMST (0-12) = 1.74 months (0.69-2.76). CONCLUSION: This Bayesian rIPD-based reanalysis provides PH-robust estimands, indicating early OS benefit with uncertain later effects, and favorable PFS over 0-12 months with erdafitinib.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。